CFM
CGTX icon

Catalyst Funds Management’s Cognition Therapeutics CGTX Stock Holding History

Catalyst Funds Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.1K Buy
+52,800
New +$61.5K 0.01% 553

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Catalyst Funds Management's CGTX Position: Q1 2026 in Review

Catalyst Funds Management opened a new position in Cognition Therapeutics (CGTX) in Q1 2026: 52,800 shares worth $40.1K. The stake represents 0.01% of the portfolio and ranks #553 among its holdings.

75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Catalyst Funds Management held 52,800 shares of Cognition Therapeutics worth $40.1K as of Q1 2026.
  • Cognition Therapeutics was a new Catalyst Funds Management position in Q1 2026.
  • Cognition Therapeutics made up 0.01% of Catalyst Funds Management's portfolio in Q1 2026, its #553 holding.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.